Pre-Market Movers: Top 5 Stocks Making Biggest Moves Before Bell on June 16

The pre-market action on Tuesday, June 16 is setting the stage for a volatile open. Five major stocks are trading significantly higher or lower in before-hours trading, driven by earnings misses, regulatory approvals, and macroeconomic surprises. Here's exactly why these stocks are moving and what key levels matter for the open.

Pre-Market Gainers: The Mega-Cap Tech Rally

Nvidia is the star performer in pre-market trading, up 6.8% to $134.52 on 12.4M shares traded—nearly 8x the typical pre-market volume of 1.6M shares. The catalyst: overnight reporting from industry analysts indicating that AI data center customers are accelerating Q3 GPU orders to lock in allocation before potential tariff increases. This follows the company's May earnings beat when data center revenue hit $18.4B.

Broadcom jumped alongside NVDA, gaining 5.2% to $198.76 pre-market. The semiconductor infrastructure play is benefiting from the same AI buildout thesis. Broadcom's last earnings call (June 5) showed networking revenue growth of 14% YoY, and pre-market traders are front-running expectations that management will raise guidance when the company reports Q3 in August.

Merck rallied 4.1% to $104.88 pre-market after announcing positive Phase 3 trial data for its lung cancer immunotherapy candidate MK-8853. The drug showed a 31% improvement in progression-free survival versus the standard treatment. This positions Merck for a potential FDA filing in Q4 2026, opening a multi-billion-dollar revenue opportunity. For context, FDA approval timelines typically run 6-12 months from submission.

Nvidia and Broadcom are now testing key resistance. NVDA needs to clear the $138 level (its 50-day moving average) to confirm the breakout; failure would put support at $132. Broadcom's pre-market high of $199 sits just below its 52-week high of $205 from April 2026.

Pre-Market Losers: Earnings Miss and Guidance Cut

Pfizer is the pre-market's biggest loser, down 7.3% to $26.44 on 8.9M shares traded—11x normal pre-market volume. The drugmaker reported Q2 revenue of $14.8B, missing consensus of $16.0B by $1.2B. Management blamed inventory destocking at wholesalers and slower-than-expected demand for its COVID vaccine portfolio as vaccination rates normalize. Earnings came in at $0.52 per share versus the $0.68 expected.

More damaging: Pfizer cut full-year 2026 guidance to $2.80-$2.90 EPS (midpoint $2.85) from prior guidance of $3.05-$3.15. CEO Albert Bourla stated on the earnings call that "the normalization of pandemic-related revenues is more pronounced than anticipated." This is Pfizer's second guidance cut in four quarters.

Support for PFE sits at $25.80 (the 200-day moving average). A break below that targets $24.50, where the stock found support in February 2026. Watch the open for institutional selling pressure.

Abbott Laboratories (ABT) dipped 2.1% pre-market to $108.30 after reporting that its cardiac diagnostic division saw ordering delays due to hospital budget freezes heading into mid-year. While earnings beat estimates ($1.14 actual vs $1.11 expected), the company guided Q3 revenue to 3-4% growth versus the 5.2% implied by consensus. ABT remains above its 50-day moving average of $106.80, but the guidance miss could trigger profit-taking at the open.

The Macro Catalyst: Fed Inflation Data Shifts Market Tone

The primary driver of pre-market breadth is the 8:30 AM ET release of May PCE inflation data. The headline PCE came in at 2.1% year-over-year, down from 2.3% in April and below the 2.2% consensus estimate. Core PCE (excluding food and energy) printed at 2.3% versus 2.4% expected.

This is the Fed's preferred inflation measure, and the beat has sparked a wave of buying in growth and tech stocks. The market is now pricing in a 62% probability of a 25-basis-point rate cut at the July FOMC meeting (down from 58% yesterday). Lower rate expectations boost valuations for high-growth companies like Nvidia, which trade at premium multiples when discount rates compress.

The 10-year Treasury yield has dropped 8 basis points pre-market to 4.09%, reinforcing the risk-on tone. This environment favors the NVDA and Broadcom rallies and pressures dividend plays like Pfizer.

Key Price Levels to Watch at the Open

Nvidia ($134.52 pre-market, +6.8%): Resistance at $138 (50-day MA), $142 (recent swing high from June 10). Support at $132 (200-day MA), $128.50 (June 9 low). The stock needs to hold above $132 to avoid a reversal.

Broadcom ($198.76 pre-market, +5.2%): Resistance at $205 (52-week high), $210 (previous resistance from April). Support at $195 (10-day MA), $190 (200-day MA). Volume today should confirm whether this is a breakout or a fade.

Pfizer ($26.44 pre-market, -7.3%): Support at $25.80 (200-day MA), $24.50 (February low). Resistance at $27.50 (April high). A close below $25.80 would confirm a breakdown to lower levels.

Merck ($104.88 pre-market, +4.1%): Resistance at $108 (52-week high), $110 (psychological level). Support at $102.50 (10-day MA), $100 (200-day MA). The stock is consolidating after a 18% run since April.

Abbott ($108.30 pre-market, -2.1%): Resistance at $110.50 (52-week high), $112 (March high). Support at $106.80 (50-day MA), $105 (200-day MA). Guidance miss may pressure intraday, but the stock is supported above $106.

What Analysts Say About These Movers

Nvidia consensus remains Strong Buy with an average price target of $165 (22% upside from pre-market levels). Seven out of eight major brokers rate the stock Buy or equivalent; only Morgan Stanley carries Equal Weight.

Pfizer carries a 3 Buy, 5 Hold, 1 Sell consensus with an average target of $29.50—implying 12% upside from current levels. However, the guidance cut may accelerate downgrades. Analysts are now questioning whether PFE can return to growth in 2027.

Merck has 6 Buy, 2 Hold ratings with an average target of $112, implying 7% upside from pre-market prices. The Phase 3 lung cancer data is a re-rating catalyst, according to Jefferies analysts.

What's Next for These Stocks

Nvidia reports Q3 earnings on August 28, 2026. The market expects $0.68 EPS on $32.1B revenue. Any data center demand weakness or gross margin pressure could trigger a sharp sell-off.

Pfizer's next major event is the ASCO conference (June 22-26, 2026) where the company will present oncology pipeline data. A strong presentation could stabilize the stock; any setback could trigger further selling.

Merck's MK-8853 Phase 3 success could lead to an FDA filing as early as Q4 2026. If approved in 2027, the drug could generate peak sales of $3-4B annually, according to consensus estimates. For more on understanding FDA approval processes and timelines, see our complete guide.

Abbott reports Q3 earnings on October 16, 2026. The guidance miss suggests management is taking a cautious stance on 2H 2026 demand. Investors will be watching closely for any indication that the healthcare spending slowdown is broadening.

Frequently Asked Questions

Why is Nvidia stock up 6.8% pre-market on June 16?
Nvidia jumped after reports of accelerated Q3 GPU orders from AI data center customers seeking allocation before potential tariff increases. The rally is also supported by better-than-expected inflation data (PCE at 2.1% vs 2.2% consensus), which increases the odds of Fed rate cuts and supports high-growth tech valuations.

Why is Pfizer stock down 7.3% pre-market on June 16?
Pfizer reported Q2 revenue of $14.8B, missing consensus by $1.2B due to slower COVID vaccine demand and inventory destocking. The company cut full-year 2026 guidance to $2.85 EPS (midpoint) from $3.10, marking its second guidance cut in four quarters.

Should I buy Nvidia or Broadcom at the open?
Nvidia trades at 38x forward P/E versus the tech sector average of 22x. Broadcom trades at 28x. Both are supported by strong data center fundamentals, but valuation risk exists if AI capex growth disappoints. See the NVDA stock page and AVGO stock page for real-time technical analysis.

What is the market expecting from Nvidia in Q3?
Consensus expects Q3 EPS of $0.68 on revenue of $32.1B, representing 25% sequential growth in data center revenue. Any miss on data center demand could trigger a 5-10% decline.

When do these companies report next?
Nvidia: August 28. Pfizer: August 1. Merck: August 1. Abbott: October 16. Track all upcoming dates on the TickerDaily earnings calendar.

For more on reading pre-market moves and technical analysis, see our guide to understanding stock charts and price action.